# The Safety Profile of a Portfolio of Hyaluronic Acid-Based Soft Tissue Fillers Manufactured Using MACRO Technology: A Systematic Review of Clinical Evidence

**Authors:** Konstantin Frank, Said Hilton, Martina Kerscher, Doris Grablowitz, Daisy Kopera, Monika Sulovsky, Leonid Kursinov

PMC · DOI: 10.3390/life16010110 · Life · 2026-01-13

## TL;DR

This study reviews the safety of hyaluronic acid-based fillers made with MACRO technology, finding they have a strong safety profile with mostly mild and temporary side effects.

## Contribution

The study provides a systematic evaluation of safety outcomes specific to HA fillers manufactured using MACRO technology.

## Key findings

- Common short-term adverse events included mild swelling, pain, and bruising that resolved within two weeks.
- Severe or serious treatment-related events were rare, with only one reported across all studies.
- Long-term adverse events were infrequent and mild, with no granulomas or hypersensitivity observed.

## Abstract

Hyaluronic acid (HA)-based fillers are widely used in aesthetic dermatology for their biocompatibility, reversibility, and safety; however, adverse events (AEs) may occur. This review evaluated the safety profile, focusing on short- and long-term AEs, of HA fillers manufactured with MACRO (MAtrix CROsslinking) Core Technology, encompassing both current saypha and former Princess products. A systematic PubMed search identified prospective clinical trials assessing safety outcomes following facial aesthetic use of these fillers. Eleven studies including 947 patients met the inclusion criteria. The most common short-term AEs were transient swelling, injection site pain, and bruising, which were predominantly mild to moderate and resolved within two weeks. Severe or serious treatment-related events were rare, with only one reported across all studies. Long-term AEs, such as delayed-onset nodules or inflammatory reactions, were infrequent and mild, with no granulomas, hypersensitivity responses, or vascular complications observed. Safety outcomes were consistent across formulations and between the legacy Princess and current saypha products. Overall, the saypha HA filler portfolio demonstrates a predictable and strong safety profile within the expected range reported in the broader literature, noting the limitations of cross-study comparisons. Most AEs were related to injection trauma rather than the filler itself, supporting its continued use in clinical aesthetic practice.

## Full-text entities

- **Diseases:** pain (MESH:D010146), hypersensitivity (MESH:D004342), inflammatory (MESH:D007249), bruising (MESH:D003288), complications (MESH:D008107), trauma (MESH:D014947), swelling (MESH:D004487), granulomas (MESH:D006099)
- **Chemicals:** HA (MESH:D006820)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12842927/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12842927/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12842927/full.md

---
Source: https://tomesphere.com/paper/PMC12842927